-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
Fusion Pharmaceuticals Inc. quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from Q3 2019 to Q1 2024.
- Fusion Pharmaceuticals Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending March 31, 2024 was -$34.5M, a 44.3% decline year-over-year.
- Fusion Pharmaceuticals Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending March 31, 2024 was -$105M, a 14.5% decline year-over-year.
- Fusion Pharmaceuticals Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was -$94.2M, a 7.08% decline from 2022.
- Fusion Pharmaceuticals Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$88M, a 8.33% decline from 2021.
- Fusion Pharmaceuticals Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was -$81.2M, a 3.73% decline from 2020.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)